SubHero Banner

Intelence® (etravirine) – Expanded indication

July 16, 2018 - The FDA announced the approval of Janssen’s Intelence (etravirine), in combination with other antiretroviral (ARV) agents, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in ARV treatment-experienced patients ages 2 years and older, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor and other ARV agents.

Download PDF